A new medication for the worst addiction Charles P. O’Brien Clinical Trials Report 03 October 2007 Pages: 347 - 348
Genetics and smoking behavior Robert A. SchnollTerrance A. JohnsonCaryn Lerman OriginalPaper 03 October 2007 Pages: 349 - 357
Why buprenorphine is so successful in treating opiate addiction in France M. FatseasMarc Auriacombe OriginalPaper 03 October 2007 Pages: 358 - 364
Targeted modulators of the endogenous cannabinoid system: Future medications to treat addiction disorders and obesity David R. JaneroAlexandros Makriyannis OriginalPaper 03 October 2007 Pages: 365 - 373
Treatment of patients comorbid for addiction and other psychiatric disorders Kathleen T. BradyMarcia L. VerduinBryan K. Tolliver OriginalPaper 03 October 2007 Pages: 374 - 380
The future of vaccines in the management of addictive disorders Frank M. OrsonBerma M. KinseyThomas R. Kosten OriginalPaper 03 October 2007 Pages: 381 - 387
Sleep disturbances and ADHD medications Anthony L. Rostain Clinical Trials report 03 October 2007 Pages: 399 - 400
Recent advances in structural and functional brain imaging studies of attention-deficit/hyperactivity disorder A. M. Clare KellyDaniel S. MarguliesF. Xavier Castellanos OriginalPaper 03 October 2007 Pages: 401 - 407
When ADHD and substance use disorders intersect: Relationship and treatment implications Timothy E. WilensSteven Fusillo OriginalPaper 03 October 2007 Pages: 408 - 414
Concurrent ADHD and bipolar disorder Russell E. Scheffer OriginalPaper 03 October 2007 Pages: 415 - 419
Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults Christopher GibbinsMargaret Weiss OriginalPaper 03 October 2007 Pages: 420 - 426
Current status of cognitive-behavioral therapy as a psychosocial treatment for adult attention-deficit/hyperactivity disorder J. Russell Ramsay OriginalPaper 03 October 2007 Pages: 427 - 433
ADHD genetics: 2007 update Josephine EliaMarcella Devoto OriginalPaper 03 October 2007 Pages: 434 - 439